Showing 4071-4080 of 5623 results for "".
- Himalayan Cataract Project Appoints Katherine G. Overbey as CEOhttps://modernod.com/news/himalayan-cataract-project-appoints-katherine-g-overbey-as-ceo/2481070/The Himalayan Cataract Project (HCP) has named Katherine G. Overbey (K-T) its new Chief Executive Officer, effective as of October 4, 2022. As HCP enters its 28th year, HCP’s Board of Directors anticipates that Ms. Overbey will guide the organization in its mission to c
- iOR Partners Appoints Health Care Industry Veteran James R. Williams as New President and CEOhttps://modernod.com/news/ior-partners-welcomes-health-care-industry-veteran-as-new-president-and-ceo/2481068/iOR Partners announced that James R. Williams has been appointed to serve as the company’s new President and CEO. Mr. Williams joined iOR as Chief Operating Officer (COO) earlier this year and served on the iOR Board of Directors for 2 years. Mr. Williams brings over 30
- First US Patient Receives Autologous Stem Cell Therapy to Treat Dry AMDhttps://modernod.com/news/first-us-patient-receives-autologous-stem-cell-therapy-to-treat-dry-amd/2481061/At the National Institutes of Health, a surgical team successfully implanted a patch of tissue made from patient cells with the goal of treating advanced dry age-related macular degeneration (AMD), also known as geographic atrophy. The patient received the therapy as part of
- Isarna Therapeutics Presents Update From Phase 2 BETTER Study in Wet AMD and DME at the EURETINA Meetinghttps://modernod.com/news/isarna-therapeutics-presents-update-from-phase-2-better-clinical-study-in-wet-amd-and-dme-at-the-euretina-meeting/2481056/Isarna Therapeutics presented an update from its ISTH0036 clinical development program and the ongoing BETTER Study at the EURETINA meeting in Hamburg, Germany on September 1st, 2022. Marion Munk, MD, PhD, FEBO, and the CMO of Isarna Therapeutics provided initial positive safety results and effic
- Bausch + Lomb Announces Strategic Partnership With Munich Surgical Imaging GmbHhttps://modernod.com/news/bausch-lomb-announces-strategic-partnership-with-munich-surgical-imaging-gmbh-1/2481053/Bausch + Lomb announced its strategic partnership with Munich Surgical Imaging GmbH (MSI)—a wholly‐owned subsidiary of Heidelberg Engineering GmbH. Based in Munich, Germany, MSI develops state‐of‐the art digital visualization and image‐guided surgical applications. The new MSI platform, dev
- Outlook Therapeutics Resubmits Biologics License Application to FDA for Wet AMD Drug Candidate ONS-5010https://modernod.com/news/outlook-therapeutics-re-submits-biologics-license-application-for-ons-5010-as-a-treatment-for-wet-amd-to-the-fda/2481052/Outlook Therapeutics announced it has resubmitted its biologics license application (BLA) to the FDA for ONS-5010, an investigational ophthalmic therapy which, if approved, will be branded as Lytenava (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD
- Haag-Streit Opens New Surgical Microscope Production Site in Aesch, Switzerlandhttps://modernod.com/news/haag-streit-opens-new-surgical-microscope-production-site-in-aesch-switzerland/2481047/Haag-Streit announced the opening of a new state-of-the-art microscope production site in Aesch, Switzerland. In September 2021, Haag-Streit decided to reposition and focus solely on ophthalmology and the production and future development of the
- Apellis Announces 24-Month Results in Phase 3 Studies Examining Pegcetacoplan in Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-24-month-results-showing-increased-effects-over-time-with-pegcetacoplan-in-phase-3-derby-and-oaks-studies-in-geographic-atrophy-ga/2481045/Apellis Pharmaceuticals announced topline data at 24 months showing increased effects over time with intravitreal pegcetacoplan, an investigational, targeted C3 therapy, in the phase 3 DERBY and OAKS studies in geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- Glaukos Licenses Iveena’s Investigational Keratoconus Therapyhttps://modernod.com/news/glaukos-licenses-iveenas-investigational-keratoconus-therapy/2481044/Glaukos has acquired an exclusive global license to develop and commercialize iVeena Delivery Systems' investigational pharmacologic treatment for keratoconus, IVMED-80. As part of the agreement, Glaukos paid $10 million upfront and will assume all costs associated with development
- Oculis Announces Publication of Phase 2 Data Showing Eye Drop Drug Candidate Relieves Persistent Ocular Discomfort in Severe Dry Eye Diseasehttps://modernod.com/news/oculis-announces-publication-of-phase-2-data-showing-topical-eye-drop-drug-candidate-ocs-02-relieves-persistent-ocular-discomfort-in-severe-dry-eye-disease/2481042/Oculis announced that the results of the double blinded, multicenter and placebo controlled phase 2 clinical trial assessing the effect of topical licaminlimab (OCS-02) on global ocular discomfort in patients with severe dry eye disease (DED) has been published by the journal C